Fenofibrate API and particle size: why micronisation is a formulation question

How particle-size distribution affects your dissolution profile — and what to specify.

What Fenofibrate is used for

Fenofibrate (CAS 49562-28-9) is a fibrate-class, PPAR-alpha agonist used as the active ingredient in lipid-regulating formulations, typically to manage elevated triglycerides and cholesterol. Full specification and sourcing detail is available on our Fenofibrate API product page.

Particle size is a specification, not a preference

Fenofibrate’s bioavailability is closely tied to particle size — this is exactly why multiple particle-size grades (standard, micronized, nanocrystallized) exist across different finished formulations in the market. Confirm which particle-size specification your formulation requires before requesting a quote; assuming “micronized” without a confirmed particle-size distribution (D10/D50/D90) range is a common and avoidable sourcing mistake.

Grade differences and monograph considerations

Pharmacopoeial grade (IP/BP/USP/EP) governs the impurity and identification tests your filing needs to reference, and — for Fenofibrate specifically — some monographs address particle-size-related dissolution behavior more explicitly than others. Confirm which monograph your filing is built against before assuming grade equivalence.

Why particle-size data belongs on every Certificate of Analysis for this compound

For most APIs, a Certificate of Analysis focuses on assay and impurity data. For a particle-size-sensitive compound like Fenofibrate, the CoA should also report the actual particle-size distribution for that batch — not just a compliance statement against a target range. Ask for this explicitly; it’s one of the checks in our general buyer’s checklist for choosing an API manufacturer, applied specifically to this compound.

Packaging, storage and handling in practice

Standard packing is 1 kg, 5 kg and 25 kg HDPE drums with double LDPE liners; other configurations on request. The material should be stored in a tightly closed container, protected from light and moisture, at controlled room temperature. Confirm the exact pack size and any specific handling needs for particle-size-controlled material at enquiry stage.

Documentation to request before the first PO

• Batch-specific Certificate of Analysis including particle-size distribution (D10/D50/D90), not just assay
• Confirmed pharmacopoeial grade and monograph reference matching your filing
• Current GMP certification type and scope — see our GMP compliance checklist
• Confirmation of consistent micronization process between batches

A short checklist before you commit

• Required particle-size specification (D10/D50/D90) confirmed with your formulation team first
• Grade and monograph reference confirmed against your filing
• Sample CoA reviewed for actual particle-size data, not just an assay figure
• Micronization process consistency confirmed in writing

Frequently asked questions

Why does particle size matter more for Fenofibrate than for many other APIs? Its bioavailability is closely linked to particle size, which is why standard, micronized, and nanocrystallized grades exist across different finished-product formulations in the market — the right one depends entirely on your formulation, not a general default.

Should I request micronized Fenofibrate by default? Not necessarily — this depends on your specific formulation and bioavailability target; confirm the required particle-size distribution with your own formulation team before specifying a grade.

Is particle-size data typically included on a standard Certificate of Analysis? Not always by default — ask for it explicitly for a particle-size-sensitive compound like this one, since a generic CoA template may only report assay and impurity data.

Do you offer more than one particle-size grade of Fenofibrate? Particle-size options are available on request — share your required D10/D50/D90 and we will confirm what we can supply.